ATE156116T1 - Auf aromatischen sulfonamiden basierende hydroxamsäurederivate - Google Patents

Auf aromatischen sulfonamiden basierende hydroxamsäurederivate

Info

Publication number
ATE156116T1
ATE156116T1 AT92924883T AT92924883T ATE156116T1 AT E156116 T1 ATE156116 T1 AT E156116T1 AT 92924883 T AT92924883 T AT 92924883T AT 92924883 T AT92924883 T AT 92924883T AT E156116 T1 ATE156116 T1 AT E156116T1
Authority
AT
Austria
Prior art keywords
hydroxamic acid
cell growth
acid derivatives
derivatives based
inhibiting
Prior art date
Application number
AT92924883T
Other languages
English (en)
Inventor
Mitsuaki Ohtani
Hitoshi Arita
Kenji Sugita
Takaharu Matsuura
Kazuhiro Shirahase
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE156116T1 publication Critical patent/ATE156116T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
AT92924883T 1991-12-10 1992-12-07 Auf aromatischen sulfonamiden basierende hydroxamsäurederivate ATE156116T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35079391 1991-12-10

Publications (1)

Publication Number Publication Date
ATE156116T1 true ATE156116T1 (de) 1997-08-15

Family

ID=18412912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924883T ATE156116T1 (de) 1991-12-10 1992-12-07 Auf aromatischen sulfonamiden basierende hydroxamsäurederivate

Country Status (10)

Country Link
US (1) US5534654A (de)
EP (1) EP0570594B1 (de)
JP (1) JP3342485B2 (de)
KR (1) KR100236806B1 (de)
AT (1) ATE156116T1 (de)
DE (1) DE69221290T2 (de)
DK (1) DK0570594T3 (de)
ES (1) ES2107557T3 (de)
GR (1) GR3024740T3 (de)
WO (1) WO1993012075A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027699A1 (en) * 1994-04-06 1995-10-19 Nippon Shinyaku Co., Ltd. Aminostilbazole derivative and medicine
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
AR011057A1 (es) * 1997-01-08 2000-08-02 Smithkline Beecham Corp Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
JP2001026506A (ja) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd スルホンアミド誘導体
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2000069465A1 (en) * 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP1233958B1 (de) 1999-11-23 2011-06-29 MethylGene Inc. Inhibitoren für histone-deacetylase
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
MXPA02010089A (es) * 2000-04-13 2004-08-19 Hsc Res Dev Lp Compuestos para modular la proliferacion celular.
EP1752446A3 (de) * 2000-04-13 2007-03-21 HSC Research and Development Limited Partnership Verbindungen für die Modulation der Proliferation von Zellen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE310719T1 (de) * 2000-09-29 2005-12-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
US6888027B2 (en) * 2000-09-29 2005-05-03 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US8026280B2 (en) * 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AU2003299757A1 (en) * 2002-12-19 2004-07-14 Elan Pharmaceuticals Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
PL1725528T3 (pl) * 2004-03-11 2013-12-31 4Sc Ag Sulfonylopirole jako inhibitory HDAC
JP2007530455A (ja) 2004-03-26 2007-11-01 エイチエスシー リサーチ アンド ディベロップメント リミテッド パートナーシップ 細胞増殖を調節する化合物
EP1841747B1 (de) * 2005-01-14 2012-09-05 SK Biopharmaceuticals Co., Ltd. Derivate von oxazolhydroxamischer säure und ihre verwendung
CA2599538C (en) 2005-03-15 2013-07-30 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
CA2603398A1 (en) * 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
ES2381962T3 (es) 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
AU2006298881A1 (en) 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
RU2008135979A (ru) 2006-02-07 2010-03-20 Астеллас Фарма Инк. (Jp) Соединения гидроксиакрилаимда
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
EP2100878A1 (de) 2008-03-12 2009-09-16 4Sc Ag Neuartiges Verfahren zur Herstellung von Sulphonylpyrrole als HDAC-Hemmer
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
CA2740952C (en) * 2008-10-22 2015-12-29 Ian L. Scott Compounds for treating ophthalmic diseases and disorders
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
JP2015504056A (ja) * 2011-12-29 2015-02-05 ファーマサイクリックス,インク. ヒストンデアセチラーゼ8の阻害剤としての珪皮酸ヒドロキシアミド
AU2014369153B2 (en) 2013-12-18 2017-09-21 Astex Therapeutics Limited Nrf2 regulators
EA201792028A1 (ru) 2015-03-13 2018-04-30 Форма Терапьютикс, Инк. Альфа-цинамидные соединения и композиции как ингибиторы hdac8
CN108137557B (zh) 2015-06-15 2021-09-07 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂
CA2988338C (en) 2015-06-15 2024-05-14 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
EP3461488A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination aus einem dbait-molekül und einem hdac-inhibitor zur behandlung von krebs
EP3461480A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination von checkpoint-hemmern des dna-schädigungsantwort-zellzyklus und belinostat zur behandlung von krebs
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20250213523A1 (en) 2022-04-05 2025-07-03 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
KR102758428B1 (ko) 2022-10-04 2025-01-21 유영훈 열선용 커넥션 키트
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2984077B2 (ja) * 1990-04-19 1999-11-29 塩野義製薬株式会社 スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体

Also Published As

Publication number Publication date
EP0570594A1 (de) 1993-11-24
DE69221290D1 (de) 1997-09-04
EP0570594B1 (de) 1997-07-30
GR3024740T3 (en) 1997-12-31
DE69221290T2 (de) 1998-01-15
US5534654A (en) 1996-07-09
WO1993012075A1 (fr) 1993-06-24
ES2107557T3 (es) 1997-12-01
DK0570594T3 (de) 1997-08-25
JP3342485B2 (ja) 2002-11-11
KR930703243A (ko) 1993-11-29
KR100236806B1 (ko) 2000-01-15
EP0570594A4 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
ATE156116T1 (de) Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
ATE223378T1 (de) Prolineamid-derivate
ATE255579T1 (de) Pyrrolidin-derivate die eine phospholipase-a2- hemmende wirkung haben
DK0658548T3 (da) Benzensylfonamidderivat og fremgangsmåde til fremstilling deraf
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
EP0630898A4 (de) Heilmittel für thrombozytopenia.
NO923721D0 (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
YU46998B (sh) Postupak za dobijanje derivata cefema i medjuproizvoda za iste
DE69021855D1 (de) Quinazolinderivate und ihre Herstellung.
KR920701240A (ko) 글루타티온 유도체
ATE248598T1 (de) Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate
MX9206930A (es) Nuevos compuestos
FI964303A0 (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine
DE69627519D1 (de) Sesquiterpen-derivate mit antiviraler aktivität
DK0466662T3 (da) 6,7-Disubstituerede-2-aminotetraliner, der er aktive som immunmodulatorer, samt farmaceutiske præparater indeholdende sådanne forbindelser
BR9206978A (pt) Composição farmacêutica para inibir infecção com vírus da aids
ATE154243T1 (de) Hemmstoff der blutgefässhypertrophie
EP1031351A4 (de) Mittel gegen leishmaniasis, enthaltend glucopyrnosederivat als aktiven inhaltsstoff
TH13254A (th) ฟธาแลซีนชนิดใหม่ที่ประกอบด้วยอีเธอร์หรือไธโออีเธอร์ที่ตำแหน่ง 1-และกรรมวิธีการเตรียม

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee